Skip to main content
Premium Trial:

Request an Annual Quote

PathGroup, CCE Partner to Provide PGx Capabilities to Community-based Oncologists

NEW YORK (GenomeWeb) – PathGroup and Cancer Clinics of Excellence today announced a partnership aimed at improving the ability of community-based oncologists to make personalized therapeutic decisions.

CCE has chosen PathGroup as a preferred laboratory service provider, and oncologists in CCE's network will now have access to tests and data generated by PathGroup using its SmartGenomics platform, which generates information about patient drug targets so physicians can make more precise, personalized therapeutic recommendations.

SmartGenomics uses several different technologies, including next-generation sequencing, array comparative genomic hybridization, immunohistochemistry, and fluorescent in situ hybridization, to profile a patient's cancer. The platform is supported by a bioinformatics pipeline from GenoSpace and Thomson Reuters, and provides oncologists with prognostic, predictive, and therapeutic information, and links the findings with clinical trial options, according to PathGroup.

Pranil Chandra, director of molecular pathology services at PathGroup, said in a statement that 80 percent of cancer patients are currently seen by community-based oncologists, and SmartGenomics provides them with access to academic-level medicine and cutting-edge therapies.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.